Tests a heart-lung support device in children with severe heart failure
Tests a heart-lung support device and two blood thinners in children with heart failure.
Plain-language title generated from the registry record
Registry title: Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
Key facts
- Where
- Dallas, Durham, New York, Palo Alto, and Seattle, United StatesSee the 5 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 16 years old?
Source: NCT06080074, who can take part
Where in United States
- Children's Health DallasDallas, United StatesTaking people
- Duke University HospitalDurham, United StatesTaking people
- Cuimc/NyphNew York, United StatesTaking people
- Lucile Packard Children's HospitalPalo Alto, United StatesTaking people
- Seattle Children's HospitalSeattle, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stanford University
- Trial code
- NCT06080074
- Record updated
- 10 August 2026
- Original description
There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to:Read full original descriptionShow less
Multicenter Trial to Evaluate the Safety and Effectiveness of the Cardiohelp System for up to 30 Days of Support in Children With Severe Cardiac Failure
There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to:
1. To evaluate the safety and effectiveness of the Cardiohelp Device for VA-ECMO (heart-lung support) for up to 30 days of support in children with severe heart failure with the goal to support its FDA clearance in children. 2. To evaluate heparin versus bivalirudin as the primary blood thinner (anticoagulant) in a randomized trial of children supported with the Cardiohelp ECMO System with the goal to plan a phase III (pivotal) randomized clinical trial
The main questions the Cardiohelp single-arm trial seeks to answer are:
* What is the safety and effectiveness of the Cardiohelp device for pediatric ECMO? * Should the Cardiohelp device be FDA-cleared for children based on the results of the study? * What are the optimal performance specifications of the Cardiohelp device in children?
The main questions the blood thinner randomized trial seeks to answer are:
* Which blood thinner is more promising (i.e., more effective and safer) in children on the Cardiohelp device? * How should a pivotal trial of heparin vs. bivalirudin be designed so it is the most informative and efficient to determine the best blood thinner?
Children who are receiving the Cardiohelp device will be approached and consented to participate if interested. For the Cardiohelp device trial, participants will undergo a standardized data collection to estimate survival to 30 days and the prevalence of serious adverse events like stroke, bleeding, and hemolysis. For the blood thinner randomized trial, participants will be randomized 1:1 to blood thinner strategy to determine which blood thinner has the fewest bleeding and clotting complications.
For the Cardiohelp single-arm trial, participant outcomes will be compared to performance goals (PG) derived from the ECMO literature. For the blood thinner randomized trial, the amount of bleeding and clotting will be measured.
The study is funded by an R01 grant from the FDA's Office of Orphan Product Development (OOPD).
Inclusion: Age 0 to 16 years of age (i.e., <17 years); Body weight 2.5 to 80 kilograms; VA-ECMO use for primary cardiac failure using the Cardiohelp system; First ECMO run during the current hospitalization; Written informed consent from the parent or legally appointed representative (LAR).
Exclusion: Allergy or contraindication to receiving UFH or bivalirudin as a primary anticoagulant on ECMO; Bleeding or coagulopathy that is a contraindication to anticoagulation; Irreversible renal, hepatic or lung failure; Stroke or uncertain neurological status within the past 30 days; VV-ECMO or ECMO for primary respiratory failure; Failure to separate from cardiopulmonary bypass; Gestationally-corrected age <37 weeks; Severely malnourished; Use of an ECMO system other than the Cardiohelp; Goals of patient to focus on comfort measures only; Patients who are pregnant or breastfeeding; Unable to undergo randomization within 30 hours following ECMO cannulation (randomized cohort only).